• LAST PRICE
    1.6300
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    1.2000/ 3
  • Ask / Lots
    1.7500/ 2
  • Open / Previous Close
    0.0000 / 1.6300
  • Day Range
    ---
  • 52 Week Range
    Low 1.1900
    High 2.4000
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 1.58
TimeVolumeDYAI
09:45 ET2001.6497
09:54 ET12001.6499
12:05 ET1001.64
01:24 ET4001.64
01:39 ET2001.6
02:31 ET13711.6399
03:07 ET4801.625
03:14 ET2501.62
03:45 ET5001.61
03:50 ET17001.63
03:56 ET1001.61
03:57 ET3071.63
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesDYAI
Dyadic International Inc
47.0M
-6.8x
---
United StatesEFTR
eFFECTOR Therapeutics Inc
49.6M
-0.7x
---
United StatesOMIC
Singular Genomics Systems Inc
38.2M
-0.4x
---
United StatesMRKR
Marker Therapeutics Inc
38.5M
-2.7x
---
United StatesUNCY
Unicycive Therapeutics Inc
50.7M
-0.8x
---
United StatesTCRT
Alaunos Therapeutics Inc
29.8M
-0.8x
---
As of 2024-03-28

Company Information

Dyadic International, Inc. is a global biotechnology platform company with operations in the United States. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for industrial applications. This technology is based on the Thermothelomyces heterothallica fungus, namely C1. The C1-cell protein production platform is a robust and versatile thermophilic filamentous fungal expression system for the development and production of biologic products, including enzymes and other proteins for human and animal health. The Company also developed the Dapibus thermophilic filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of proteins, metabolites and other biologic products for use in non-pharmaceutical applications, such as food, nutrition and wellness.

Contact Information

Headquarters
1044 NORTH U.S. HIGHWAY ONE, SUITE 201JUPITER, FL, United States 33477
Phone
561-743-8333
Fax
561-743-8343

Executives

Non-Executive Independent Chairman of the Board
Michael Tarnok
President, Chief Executive Officer, Director
Mark Emalfarb
Chief Financial Officer
Ping Rawson
Executive Vice President - Business Development
Doug Pace
Vice President of Research and Business Development
Ronen Tchelet

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$47.0M
Revenue (TTM)
$3.0M
Shares Outstanding
28.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.58
EPS
$-0.24
Book Value
$0.39
P/E Ratio
-6.8x
Price/Sales (TTM)
15.9
Price/Cash Flow (TTM)
---
Operating Margin
-280.81%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.